Table 3.
Imaging response
| Total n (%) |
DEB-TACE n (%) |
Y90 n (%) |
Ablation n (%) |
|
|---|---|---|---|---|
| RECIST | ||||
| PD | 13 (54.2) | 7 (30.4) | 2 (33.3) | 4 (80.0) |
| SD | 10 (41.7) | 6 (26.1) | 4 (66.7) | 0 (0) |
| PR | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| CR | 1 (4.2) | 0 (0) | 0 (0) | 1 (20.0) |
|
| ||||
| mRECIST | ||||
| PD | 9 (37.5) | 3 (13.0) | 3 (50.0) | 3 (60.0) |
| SD | 5 (20.8) | 3 (13.0) | 2 (33.3) | 0 (0) |
| PR | 5 (20.8) | 4 (17.4) | 1 (16.7) | 0 (0) |
| CR | 5 (20.8) | 3 (13.0) | 0 (0) | 2 (40.0) |
DEB-TACE, doxorubicin eluting bead transarterial chemoembolization; Y90, yttrium-90; RECIST, response evaluation criteria in solid tumors; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; mRECIST, modified response evaluation criteria in solid tumors.